Painkiller may also fight bacteria in PCA pumps
NCT ID NCT07285759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This lab study tested whether levobupivacaine, a local anesthetic used in patient-controlled analgesia (PCA) pumps, can kill Staphylococcus aureus bacteria. Researchers mixed the drug at two common concentrations with bacteria in a lab model and counted how many bacteria survived. The goal is to see if the anesthetic itself might help prevent infections in patients using these pain pumps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Levobupivacaine
- What this could lead to
- If levobupivacaine shows strong antibacterial effects, it could help reduce infection risk in patients using PCA pumps for pain relief.
- What could go wrong
- This is a small lab study, not a human trial. Results may not translate to real-world use, and the effect might be too weak to matter clinically.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BACTERIAL CONTAMINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.